Literature DB >> 29511341

The stiff RhoAd from mevalonate to mutant p53.

Giovanni Sorrentino1, Fiamma Mantovani2,3, Giannino Del Sal4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29511341      PMCID： PMC5864227          DOI： 10.1038/s41418-018-0091-x

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN： 1350-9047            Impact factor:   15.828


× No keyword cloud information.
  15 in total

1.  SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.

Authors:  D Li; N D Marchenko; U M Moll
Journal:  Cell Death Differ       Date:  2011-06-03       Impact factor: 15.828

2.  Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.

Authors:  William A Freed-Pastor; Hideaki Mizuno; Xi Zhao; Anita Langerød; Sung-Hwan Moon; Ruth Rodriguez-Barrueco; Anthony Barsotti; Agustin Chicas; Wencheng Li; Alla Polotskaia; Mina J Bissell; Timothy F Osborne; Bin Tian; Scott W Lowe; Jose M Silva; Anne-Lise Børresen-Dale; Arnold J Levine; Jill Bargonetti; Carol Prives
Journal:  Cell       Date:  2012-01-20       Impact factor: 41.582

3.  Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation.

Authors:  T Koga; S Hashimoto; K Sugio; I Yoshino; K Nakagawa; Y Yonemitsu; K Sugimachi; K Sueishi
Journal:  Int J Cancer       Date:  2001-07-20       Impact factor: 7.396

4.  Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells.

Authors:  Shinji Mizuarai; Kazunori Yamanaka; Hidehito Kotani
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

5.  Tumor suppressor p53 restricts Ras stimulation of RhoA and cancer cell motility.

Authors:  Mingxuan Xia; Hartmut Land
Journal:  Nat Struct Mol Biol       Date:  2007-02-18       Impact factor: 15.369

6.  Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells.

Authors:  Dun Li; Natalia D Marchenko; Ramona Schulz; Victoria Fischer; Talia Velasco-Hernandez; Flaminia Talos; Ute M Moll
Journal:  Mol Cancer Res       Date:  2011-04-08       Impact factor: 5.852

7.  Mutant p53 drives invasion by promoting integrin recycling.

Authors:  Patricia A J Muller; Patrick T Caswell; Brendan Doyle; Marcin P Iwanicki; Ee H Tan; Saadia Karim; Natalia Lukashchuk; David A Gillespie; Robert L Ludwig; Pauline Gosselin; Anne Cromer; Joan S Brugge; Owen J Sansom; Jim C Norman; Karen H Vousden
Journal:  Cell       Date:  2009-12-24       Impact factor: 41.582

Review 8.  HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination.

Authors:  C Boyault; K Sadoul; M Pabion; S Khochbin
Journal:  Oncogene       Date:  2007-08-13       Impact factor: 9.867

9.  Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53.

Authors:  Paul Timpson; Ewan J McGhee; Jennifer P Morton; Alex von Kriegsheim; Juliane P Schwarz; Saadia A Karim; Brendan Doyle; Jean A Quinn; Neil O Carragher; Mike Edward; Michael F Olson; Margaret C Frame; Valerie G Brunton; Owen J Sansom; Kurt I Anderson
Journal:  Cancer Res       Date:  2011-01-25       Impact factor: 12.701

10.  Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis.

Authors:  Eleonora Ingallina; Giovanni Sorrentino; Rebecca Bertolio; Kamil Lisek; Alessandro Zannini; Luca Azzolin; Luisa Ulloa Severino; Denis Scaini; Miguel Mano; Fiamma Mantovani; Antonio Rosato; Silvio Bicciato; Stefano Piccolo; Giannino Del Sal
Journal:  Nat Cell Biol       Date:  2017-12-18       Impact factor: 28.824
View more
  8 in total

Review 1.  Context is everything: extrinsic signalling and gain-of-function p53 mutants.

Authors:  Ivano Amelio; Gerry Melino
Journal:  Cell Death Discov       Date:  2020-03-23

2.  Resveratrol attenuates cerebral ischaemia reperfusion injury via modulating mitochondrial dynamics homeostasis and activating AMPK-Mfn1 pathway.

Authors:  Jinbao Gao; Haijiang Wang; Yunjun Li; Wende Li
Journal:  Int J Exp Pathol       Date:  2019-12-22       Impact factor: 1.925

Review 3.  Regulation of Adult Neurogenesis in Mammalian Brain.

Authors:  Maria Victoria Niklison-Chirou; Massimiliano Agostini; Ivano Amelio; Gerry Melino
Journal:  Int J Mol Sci       Date:  2020-07-09       Impact factor: 5.923

4.  Smyd2 conformational changes in response to p53 binding: role of the C-terminal domain.

Authors:  Balasubramanian Chandramouli; Gerry Melino; Giovanni Chillemi
Journal:  Mol Oncol       Date:  2019-05-21       Impact factor: 6.603

5.  p53-R273H Sustains ROS, Pro-Inflammatory Cytokine Release and mTOR Activation While Reducing Autophagy, Mitophagy and UCP2 Expression, Effects Prevented by wtp53.

Authors:  Maria Anele Romeo; Maria Saveria Gilardini Montani; Rossella Benedetti; Andrea Arena; Gabriella D'Orazi; Mara Cirone
Journal:  Biomolecules       Date:  2021-02-24

Review 6.  Context is everything: extrinsic signalling and gain-of-function p53 mutants.

Authors:  Ivano Amelio; Gerry Melino
Journal:  Cell Death Discov       Date:  2020-03-23

Review 7.  Do Mutations Turn p53 into an Oncogene?

Authors:  Consuelo Pitolli; Ying Wang; Mara Mancini; Yufang Shi; Gerry Melino; Ivano Amelio
Journal:  Int J Mol Sci       Date:  2019-12-11       Impact factor: 5.923

8.  Lovastatin reduces PEL cell survival by phosphorylating ERK1/2 that blocks the autophagic flux and engages a cross-talk with p53 to activate p21.

Authors:  Roberta Santarelli; Chiara Pompili; Maria Saveria Gilardini Montani; Maria Anele Romeo; Roberta Gonnella; Gabriella D'Orazi; Mara Cirone
Journal:  IUBMB Life       Date:  2021-05-21       Impact factor: 3.885
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.